Skip to Content
Merck
  • Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen.

Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen.

Nature protocols (2009-02-28)
Kenneth Smith, Lori Garman, Jens Wrammert, Nai-Ying Zheng, J Donald Capra, Rafi Ahmed, Patrick C Wilson
ABSTRACT

We describe herein a protocol for the production of antigen-specific human monoclonal antibodies (hmAbs). Antibody-secreting cells (ASCs) are isolated from whole blood collected 7 d after vaccination and sorted by flow cytometry into single cell plates. The antibody genes of the ASCs are then amplified by RT-PCR and nested PCR, cloned into expression vectors and transfected into a human cell line. The expressed antibodies can then be purified and assayed for binding and neutralization. This method uses established techniques but is novel in their combination and application. This protocol can be completed with as little as 20 ml of human blood and in as little as 28 d when optimal. Although previous methodologies to produce hmAbs, including B-cell immortalization or phage display, can be used to isolate the rare specific antibody even years after immunization, in comparison, these approaches are inefficient, resulting in few relevant antibodies. Although dependent on having an ongoing immune response, the approach described herein can be used to rapidly generate numerous antigen-specific hmAbs in a short time.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
N,N-Dimethylformamide, for molecular biology, ≥99%
Sigma-Aldrich
Glycine, suitable for electrophoresis, ≥99%
Sigma-Aldrich
Phosphate buffered saline, 10× concentrate, BioPerformance Certified, suitable for cell culture
Sigma-Aldrich
SOC Medium, For use in transformation